Cyclerion Therapeutics (CYCN) Competitors $2.45 +0.09 (+3.81%) Closing price 09/16/2025 03:51 PM EasternExtended Trading$2.39 -0.06 (-2.41%) As of 09/16/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. PYRGF, RNTX, ITRM, KLTO, MAAQ, RVPH, KZR, CASI, DARE, and AKTXShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include PyroGenesis Canada (PYRGF), Rein Therapeutics (RNTX), Iterum Therapeutics (ITRM), Klotho Neurosciences (KLTO), Mana Capital Acquisition (MAAQ), Reviva Pharmaceuticals (RVPH), Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Dare Bioscience (DARE), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Its Competitors PyroGenesis Canada Rein Therapeutics Iterum Therapeutics Klotho Neurosciences Mana Capital Acquisition Reviva Pharmaceuticals Kezar Life Sciences CASI Pharmaceuticals Dare Bioscience Akari Therapeutics Cyclerion Therapeutics (NASDAQ:CYCN) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk. Which has more volatility & risk, CYCN or PYRGF? Cyclerion Therapeutics has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Do institutionals & insiders believe in CYCN or PYRGF? 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is CYCN or PYRGF more profitable? Cyclerion Therapeutics has a net margin of -89.51% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion Therapeutics-89.51% -22.63% -20.65% PyroGenesis Canada -115.14%N/A -60.81% Which has preferable earnings & valuation, CYCN or PYRGF? Cyclerion Therapeutics has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$2M4.09-$3.06M-$0.74-3.31PyroGenesis Canada$9.14M3.96-$21.12M-$0.03-6.43 Does the media prefer CYCN or PYRGF? In the previous week, Cyclerion Therapeutics had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 2 mentions for Cyclerion Therapeutics and 0 mentions for PyroGenesis Canada. Cyclerion Therapeutics' average media sentiment score of 0.45 beat PyroGenesis Canada's score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cyclerion Therapeutics Neutral PyroGenesis Canada Neutral SummaryCyclerion Therapeutics beats PyroGenesis Canada on 8 of the 13 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.88M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-3.3121.1675.8626.51Price / Sales4.09446.35528.72123.58Price / CashN/A45.4037.1760.46Price / Book0.759.6212.796.29Net Income-$3.06M-$53.28M$3.28B$270.51M7 Day Performance3.81%1.01%0.81%1.95%1 Month Performance3.81%4.58%4.60%6.33%1 Year Performance-14.04%8.35%70.39%25.62% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics1.5296 of 5 stars$2.45+3.8%N/A-12.5%$7.88M$2M-3.3130Short Interest ↑Gap UpPYRGFPyroGenesis CanadaN/A$0.17-6.6%N/A-66.9%$32.80M$9.14M-2.9290Gap UpRNTXRein Therapeutics0.9779 of 5 stars$1.39+3.7%N/AN/A$32.40MN/A-0.529Gap DownITRMIterum Therapeutics3.1404 of 5 stars$0.68+2.7%$9.00+1,227.4%-35.9%$32.03MN/A-0.8010Positive NewsShort Interest ↓KLTOKlotho Neurosciences0.5426 of 5 stars$0.51+1.5%N/AN/A$31.21MN/A-1.13N/APositive NewsMAAQMana Capital AcquisitionN/A$3.71+0.6%N/A-36.7%$30.14MN/A0.001RVPHReviva Pharmaceuticals2.8907 of 5 stars$0.44-2.0%$5.20+1,087.2%-66.1%$29.78MN/A-0.675News CoverageAnalyst ForecastKZRKezar Life Sciences3.6109 of 5 stars$4.02+0.1%$9.00+124.2%-34.6%$29.40M$7M-0.4160CASICASI Pharmaceuticals3.7943 of 5 stars$2.35+0.2%$4.00+69.9%-70.8%$29.21M$28.54M-0.82180DAREDare Bioscience2.7001 of 5 stars$2.11-1.2%$10.00+375.1%-36.0%$28.38M$10K-0.9830Short Interest ↓AKTXAkari Therapeutics3.7038 of 5 stars$0.85flat$3.30+288.2%-76.9%$27.73MN/A0.009 Related Companies and Tools Related Companies PYRGF Competitors RNTX Competitors ITRM Competitors KLTO Competitors MAAQ Competitors RVPH Competitors KZR Competitors CASI Competitors DARE Competitors AKTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
